Ribupatide
CLevel 1 evidenceRibupatide
Basic Information
GLP-1/GIP dual receptor agonist
Hengrui's investigational once-weekly dual GLP-1/GIP receptor agonist demonstrated significant weight loss efficacy in China Phase III trials.
Efficacy Rating
Class C
No data available
No data available
China Regulatory Status
No data available
No data available
No data available
Similar Peptide Recommendations
Enisamitide
Enisamipide
GLP-1/GIP agonist, weight loss
ASC30
ASC30
Research, GLP-1, small molecules
Avexitide
Avexitide
Research, GLP-1 antagonists, hypoglycemia
Berobenatide
Berobenatide
GLP-1, Weight Loss, Obesity
Disclaimer
The content on this platform is for educational and informational purposes only and does not constitute medical advice, formulation guidance, or a guarantee of regulatory compliance. All efficacy claims are labeled with their evidence level; please consult a professional before making any decisions.